Journal Article
. 2007 May; 56(11):1743-53.
doi: 10.1007/s00262-007-0318-z.

Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival

Richard W Griffiths 1 Eyad Elkord  David E Gilham  Vijay Ramani  Noel Clarke  Peter L Stern  Robert E Hawkins  
  • PMID: 17487490
  •     69 citations


Background: Regulatory T cells are important in maintaining immune homeostasis, mediating peripheral tolerance and preventing autoimmunity. Increased frequencies of CD4(+)CD25(high )T regulatory (T(Reg)) cells have been documented in the peripheral blood of patients with several types of cancer consistent with a role in tumour escape from immunological control. We have investigated the presence of T(Reg) cells systemically and in situ in previously untreated patients with renal cell carcinoma (RCC).

Results: We have shown that there is a significant increased frequency of CD4(+)CD25(high) T cells in RCC patients (n = 49) compared to normal donors (n = 38), respectively, 2.47% versus 1.50%; P < 0.0001. We confirmed these data using the FOXP3 marker of T(Reg) cells in a subset of these patients and normal donors. The population of T(Reg) cells identified showed the expected phenotype with CD4(+)CD25(high) population in both RCC patients and normal donors contained higher proportions of CD45RO and GITR than CD4(+)CD25(-/low) populations and exhibiting suppressive activity in an anti-CD3 and anti-CD28 induced proliferation assay. CD4(+)FOXP3(+) T cells were detected in the tumour microenvironment by immunofluorescence and the numbers enumerated in lymphocytes recovered following enzymatic disaggregations of biopsies; their frequency was higher in the tumour than the peripheral blood of the same patients. The early follow up data show an association between higher peripheral blood regulatory T-cell count and adverse overall survival.

Conclusion: These data confirm the increase of T(Reg) cells in RCC patients and provide impetus to further investigate modulation of T(Reg) activity in RCC patients as part of therapy.

Forkhead box P3-positive regulatory T cells in immune surveillance and cancer.
G Ferretti, A Felici, F Cognettti.
Br J Cancer, 2007 Aug 19; 97(7). PMID: 17700566    Free PMC article.
Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.
Scott S Tykodi, John A Thompson.
Expert Opin Biol Ther, 2008 Nov 08; 8(12). PMID: 18990081    Free PMC article.
Stored red blood cell transfusion induces regulatory T cells.
Joel M Baumgartner, Christopher C Silliman, +2 authors, Martin D McCarter.
J Am Coll Surg, 2009 Feb 21; 208(1). PMID: 19228512    Free PMC article.
Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.
Christiane Geiger, Elfriede Nössner, +3 authors, Dolores J Schendel.
J Mol Med (Berl), 2009 Mar 10; 87(6). PMID: 19271159
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia.
Miroslaw J Szczepanski, Marta Szajnik, +6 authors, Michael Boyiadzis.
Clin Cancer Res, 2009 May 07; 15(10). PMID: 19417016    Free PMC article.
Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival.
A J Montero, C M Diaz-Montero, +7 authors, N Tannir.
Ann Oncol, 2009 Jun 23; 20(10). PMID: 19541791    Free PMC article.
Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer.
Zhengbin Shen, Shuang Zhou, +4 authors, Yihong Sun.
J Cancer Res Clin Oncol, 2010 Mar 12; 136(10). PMID: 20221835
Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma.
L J Chi, H T Lu, +4 authors, B Z Shen.
Clin Exp Immunol, 2010 Jul 22; 161(3). PMID: 20646003    Free PMC article.
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
Matteo Vergati, Vittore Cereda, +7 authors, Kwong Y Tsang.
Cancer Immunol Immunother, 2010 Oct 27; 60(2). PMID: 20976449    Free PMC article.
The immunoregulatory mechanisms of carcinoma for its survival and development.
Caigan Du, Yuzhuo Wang.
J Exp Clin Cancer Res, 2011 Jan 25; 30. PMID: 21255410    Free PMC article.
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.
Anita Schwandt, Jorge A Garcia, +7 authors, Brian I Rini.
J Clin Immunol, 2011 Apr 14; 31(4). PMID: 21487892
The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance.
Nona Janikashvili, Bernard Bonnotte, Emmanuel Katsanis, Nicolas Larmonier.
Clin Dev Immunol, 2011 Nov 24; 2011. PMID: 22110524    Free PMC article.
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
Charlotte M Huijts, Saskia J Santegoets, +5 authors, Hans J van der Vliet.
BMC Cancer, 2011 Dec 02; 11. PMID: 22129044    Free PMC article.
Localization of FOXP3-positive cells in renal cell carcinoma.
Katharina Sell, Peter J Barth, +7 authors, Andres Jan Schrader.
Tumour Biol, 2011 Dec 07; 33(2). PMID: 22143939
Suppression, subversion and escape: the role of regulatory T cells in cancer progression.
K Oleinika, R J Nibbs, G J Graham, A R Fraser.
Clin Exp Immunol, 2012 Dec 04; 171(1). PMID: 23199321    Free PMC article.
Increased numbers of gastric-infiltrating mast cells and regulatory T cells are associated with tumor stage in gastric adenocarcinoma patients.
Yibin Zhao, Ke Wu, +4 authors, Jiliang Wang.
Oncol Lett, 2012 Dec 04; 4(4). PMID: 23205096    Free PMC article.
Telomere length in relation to immunological parameters in patients with renal cell carcinoma.
Ulrika Svenson, Elisabeth Grönlund, +3 authors, Göran Roos.
PLoS One, 2013 Feb 06; 8(2). PMID: 23383336    Free PMC article.
Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy.
Minoru Kobayashi, Taro Kubo, +6 authors, Tatsuo Morita.
Med Oncol, 2013 Mar 30; 30(2). PMID: 23539200
Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma.
Stefanie Regine Dannenmann, Julia Thielicke, +9 authors, Maries van den Broek.
Oncoimmunology, 2013 May 21; 2(3). PMID: 23687622    Free PMC article.
Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.
James H Finke, Pat A Rayman, +3 authors, Peter A Cohen.
Cancer J, 2013 Jul 23; 19(4). PMID: 23867518    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer.
Shuang Zhou, Zhenbing Shen, +13 authors, Chunmin Liang.
PLoS One, 2013 Sep 17; 8(9). PMID: 24040244    Free PMC article.
Clinical significance of Treg cell frequency in acute myeloid leukemia.
Wenjuan Yang, Yunxiao Xu.
Int J Hematol, 2013 Oct 22; 98(5). PMID: 24142765
Update on vaccine development for renal cell cancer.
Nina Chi, Jodi K Maranchie, Leonard J Appleman, Walter J Storkus.
Open Access J Urol, 2010 Jan 01; 2. PMID: 24198621    Free PMC article.
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.
Grégoire Wieërs, Nathalie Demotte, Danièle Godelaine, Pierre Van der Bruggen.
Cancers (Basel), 2011 Jan 01; 3(3). PMID: 24212939    Free PMC article.
Minimal changes in the systemic immune response after nephrectomy of localized renal masses.
Gal Wald, Kerri T Barnes, +6 authors, Lyse A Norian.
Urol Oncol, 2014 Apr 29; 32(5). PMID: 24768357    Free PMC article.
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.
Scott S Tykodi.
Onco Targets Ther, 2014 Aug 13; 7. PMID: 25114573    Free PMC article.
CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.
Tsung Wen Chong, Fera Yiqian Goh, +6 authors, Puay Hoon Tan.
J Clin Pathol, 2014 Dec 06; 68(3). PMID: 25477528    Free PMC article.
Comparison of circulating and intratumoral regulatory T cells in patients with renal cell carcinoma.
Gati Asma, Gorrab Amal, +3 authors, Ben Ammar Elgaaied Amel.
Tumour Biol, 2015 Jan 08; 36(5). PMID: 25563193
Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in mice.
Xuan Li, Yiming Meng, +5 authors, Fengping Shan.
Cancer Biol Ther, 2015 Feb 24; 16(3). PMID: 25701137    Free PMC article.
Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients.
Jithendra Kini Bailur, Brigitte Gueckel, Evelyna Derhovanessian, Graham Pawelec.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25849846    Free PMC article.
Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma.
V Baldan, R Griffiths, R E Hawkins, D E Gilham.
Br J Cancer, 2015 Apr 14; 112(9). PMID: 25867267    Free PMC article.
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
Marina K Baine, Gabriela Turcu, +5 authors, Lucia B Jilaveanu.
Oncotarget, 2015 Sep 01; 6(28). PMID: 26317902    Free PMC article.
Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma.
Weisi Liu, Yidong Liu, +5 authors, Jiejie Xu.
Oncotarget, 2016 Feb 26; 7(12). PMID: 26910919    Free PMC article.
Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion.
Eva Juengel, Geraldine Krueger, +9 authors, Roman A Blaheta.
Oncotarget, 2016 Mar 05; 7(15). PMID: 26943029    Free PMC article.
Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
Marta Usó, Eloisa Jantus-Lewintre, +11 authors, Rafael Sirera.
Oncotarget, 2016 Jul 28; 7(33). PMID: 27463005    Free PMC article.
Monitoring of the Immune Dysfunction in Cancer Patients.
Saskia J A M Santegoets, Marij J P Welters, Sjoerd H van der Burg.
Vaccines (Basel), 2016 Sep 07; 4(3). PMID: 27598210    Free PMC article.
Lymphocyte-mediated Immune Regulation in Health and Disease: The Treg and γδ T Cell Co-conspiracy.
Kyle K Payne.
Immunol Invest, 2016 Oct 25; 45(8). PMID: 27617588    Free PMC article.
Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Azharuddin Sajid Syed Khaja, Salman M Toor, +4 authors, Eyad Elkord.
Oncotarget, 2017 Apr 08; 8(20). PMID: 28388539    Free PMC article.
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Shona Hendry, Roberto Salgado, +97 authors, Stephen B Fox.
Adv Anat Pathol, 2017 Aug 05; 24(6). PMID: 28777143    Free PMC article.
Highly Cited. Review.
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Fumi Kawakami, Kanishka Sircar, +8 authors, Jose A Karam.
Cancer, 2017 Aug 24; 123(24). PMID: 28832979    Free PMC article.
The current status of immunobased therapies for metastatic renal-cell carcinoma.
Niranjan J Sathianathen, Suprita Krishna, +4 authors, Thomas S Griffith.
Immunotargets Ther, 2017 Dec 20; 6. PMID: 29255699    Free PMC article.
Immune consequences of anti-angiogenic therapyin renal cell carcinoma.
Klaudia K Brodaczewska, Cezary Szczylik, Claudine Kieda.
Contemp Oncol (Pozn), 2018 Apr 10; 22(1A). PMID: 29628789    Free PMC article.
Profiles of tumor-infiltrating immune cells in renal cell carcinoma and their clinical implications.
Gongmin Zhu, Lijiao Pei, +5 authors, Xin Gou.
Oncol Lett, 2019 Oct 16; 18(5). PMID: 31612034    Free PMC article.
Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer.
Krishnendu Pal, Vijay Sagar Madamsetty, +3 authors, Debabrata Mukhopadhyay.
NPJ Precis Oncol, 2019 Dec 17; 3. PMID: 31840081    Free PMC article.
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
Matthew K Labriola, Kristen A Batich, +5 authors, Tian Zhang.
Clin Genitourin Cancer, 2019 Mar 13; 17(3). PMID: 30858035    Free PMC article.
Role of Chemokine (C-X-C Motif) Ligand 10 (CXCL10) in Renal Diseases.
Jie Gao, Lingling Wu, Siyang Wang, Xiangmei Chen.
Mediators Inflamm, 2020 Feb 25; 2020. PMID: 32089645    Free PMC article.
Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer.
Souptik Barua, Penny Fang, +4 authors, Steven H Lin.
Lung Cancer, 2018 Feb 08; 117. PMID: 29409671    Free PMC article.
Regulation of regulatory T cells in cancer.
Julie Stockis, Rahul Roychoudhuri, Timotheus Y F Halim.
Immunology, 2019 Apr 30; 157(3). PMID: 31032905    Free PMC article.
Regulatory T cells in cancer: where are we now?
Awen Gallimore, Sergio A Quezada, Rahul Roychoudhuri.
Immunology, 2019 Jun 22; 157(3). PMID: 31225653    Free PMC article.
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.
Afsheen Raza, Maysaloun Merhi, +4 authors, Said Dermime.
J Transl Med, 2020 Mar 30; 18(1). PMID: 32220256    Free PMC article.
Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer.
Fang Bai, Peng Zhang, +6 authors, Kejin Wu.
J Immunother Cancer, 2020 Apr 18; 8(1). PMID: 32300050    Free PMC article.
Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
Alessia Mennitto, Veronica Huber, +9 authors, Elena Verzoni.
J Clin Med, 2020 Apr 02; 9(4). PMID: 32231117    Free PMC article.
Prostaglandin E2 Reverses the Effects of DNA Methyltransferase Inhibitor and TGFB1 on the Conversion of Naive T Cells to iTregs.
Mehmet Sahin, Emel Sahin.
Transfus Med Hemother, 2020 Jul 01; 47(3). PMID: 32595429    Free PMC article.
The CCL20-CCR6 Axis in Cancer Progression.
Suguru Kadomoto, Kouji Izumi, Atsushi Mizokami.
Int J Mol Sci, 2020 Jul 28; 21(15). PMID: 32707869    Free PMC article.
BACH2 drives quiescence and maintenance of resting Treg cells to promote homeostasis and cancer immunosuppression.
Francis M Grant, Jie Yang, +15 authors, Rahul Roychoudhuri.
J Exp Med, 2020 Jun 10; 217(9). PMID: 32515782    Free PMC article.
Sarcomatoid renal cell carcinoma: biology, natural history and management.
Kyle A Blum, Sounak Gupta, +5 authors, A Ari Hakimi.
Nat Rev Urol, 2020 Oct 15; 17(12). PMID: 33051619    Free PMC article.
TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer.
Renpei Kato, Noriaki Jinnouchi, +8 authors, Wataru Obara.
Transl Oncol, 2020 Nov 01; 14(1). PMID: 33129110    Free PMC article.
The effect of CCL5 on the immune cells infiltration and the prognosis of patients with kidney renal clear cell carcinoma.
Shuheng Bai, YinYing Wu, +8 authors, Juan Ren.
Int J Med Sci, 2020 Nov 12; 17(18). PMID: 33173412    Free PMC article.
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.
Charlotte M Huijts, Inge M Werter, +9 authors, Dutch WIN-O Consortium.
Cancer Immunol Immunother, 2018 Nov 11; 68(2). PMID: 30413837    Free PMC article.
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.
Charlotte M Huijts, Sinéad M Lougheed, +8 authors, Dutch WIN-O Consortium.
Cancer Immunol Immunother, 2019 Jan 18; 68(3). PMID: 30652208    Free PMC article.
Organized immune cell interactions within tumors sustain a productive T-cell response.
Maria A Cardenas, Nataliya Prokhnevska, Haydn T Kissick.
Int Immunol, 2020 Aug 23; 33(1). PMID: 32827212    Free PMC article.
Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma.
Yuli Jian, Kangkang Yang, +10 authors, Shujing Wang.
Front Immunol, 2021 Mar 27; 12. PMID: 33767709    Free PMC article.
CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.
Sarah K Whiteside, Francis M Grant, +14 authors, Rahul Roychoudhuri.
Immunology, 2021 Apr 11; 163(4). PMID: 33838058    Free PMC article.
Development and Validation of a Radiomic Nomogram for Predicting the Prognosis of Kidney Renal Clear Cell Carcinoma.
Ruizhi Gao, Hui Qin, +13 authors, Hong Yang.
Front Oncol, 2021 Jul 24; 11. PMID: 34295804    Free PMC article.
Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma.
Sabina Davidsson, Michelangelo Fiorentino, +4 authors, Jessica Carlsson.
Eur Urol Open Sci, 2021 Aug 03; 20. PMID: 34337459    Free PMC article.
Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions.
Iris Tung, Arvind Sahu.
Front Oncol, 2021 Sep 17; 11. PMID: 34527581    Free PMC article.
From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
Jonathan Anker, Justin Miller, +2 authors, Che-Kai Tsao.
Cells, 2021 Nov 28; 10(11). PMID: 34831452    Free PMC article.
Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients.
Emma J West, Karen J Scott, +11 authors, Adel Samson.
Cancers (Basel), 2022 May 15; 14(9). PMID: 35565310    Free PMC article.